Clinical Trial Update: Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update investigating exendin-(9-39) effects on fasting adaptation and protein sensitivity in congenital hyperinsulinism; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hyperinsulinism

Drugs mentioned

• Exendin 9-39 (exendin-9-39)

Snippet

Sponsor: Diva De Leon | Conditions: Congenital Hyperinsulinism | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-01-18